Hormonal
Reallocating 30 minutes of daily sedentary time to moderate-to-vigorous physical activity (MVPA) in young, healthy, active adults increases daily energy intake by approximately 113–120 kcal and alters appetite hormones (higher fasting ghrelin, lower postprandial PYY) to compensate for energy expenditure, without affecting hedonic food reward traits.
If you are already active and healthy, increasing your moderate-to-vigorous exercise by 30 minutes a day will likely make you hungrier and cause you to eat about 120 more calories. This is your body's natural way of balancing energy. To manage weight, you must consciously account for this increased intake rather than assuming exercise alone creates a deficit. If your goal is performance, use this hunger to fuel your activity.
Reallocating 30 min/day of sedentary time to MVPA was associated with higher energy intake in free-living (+113 kcal/day, 95% CI: 34–192) and laboratory settings (+120 kcal/day, 95% CI: 55–185), along with greater postprandial hunger and prospective food consumption, reduced fullness, elevated fasting acylated ghrelin, and lower postprandial PYY.
Why this rating
Cross-sectional observational study using isotemporal substitution modeling; not a randomized controlled trial, limiting causal inference.
Source
Replacing Sedentary Time with Physical Activity and Sleep: A 24-Hour Movement Behaviour Perspective on Appetite Control
Sundus Malaikah et al. · Nutrients · 2025
DOI 10.3390/nu17193163
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →